论文部分内容阅读
目的探讨低分子肝素和普通肝素在急性冠脉综合征中的疗效差异。方法回顾性分析本院2010年1月~2013年12月期间收治的84例急性冠脉综合征患者的临床资料。结果对照组42例患者,经普通肝素治疗,总有效率为76.19%,观察组42例患者,经低分子肝素治疗,总有效率为90.48%,明显高于对照组,经比较,P<0.05,差异具有统计学意义。两组患者治疗过程中,均未出现严重出血、血小板减少及骨质疏松等明显不良反应,亦未见症状加重,不良反应比较,P>0.05,差异无统计学意义。结论低分子肝素治疗急性冠脉综合征临床疗效确切,不良反应小,值得推广应用。
Objective To investigate the therapeutic effect of low molecular weight heparin and unfractionated heparin in acute coronary syndrome. Methods The clinical data of 84 patients with acute coronary syndrome admitted in our hospital from January 2010 to December 2013 were retrospectively analyzed. Results The control group of 42 patients treated with unfractionated heparin, the total effective rate was 76.19%. The observation group of 42 patients treated with low molecular weight heparin, the total effective rate was 90.48%, significantly higher than the control group, P <0.05 , The difference was statistically significant. No significant adverse reactions such as severe hemorrhage, thrombocytopenia and osteoporosis occurred during the course of treatment in the two groups. No symptoms were found. Adverse reactions were compared, P> 0.05. There was no significant difference between the two groups. Conclusion Low molecular weight heparin in the treatment of acute coronary syndrome has definite curative effect and small adverse reactions, which is worth popularizing and applying.